EP1309728A2 - Procede d'analyse hautement parallele de polymorphismes - Google Patents
Procede d'analyse hautement parallele de polymorphismesInfo
- Publication number
- EP1309728A2 EP1309728A2 EP01942981A EP01942981A EP1309728A2 EP 1309728 A2 EP1309728 A2 EP 1309728A2 EP 01942981 A EP01942981 A EP 01942981A EP 01942981 A EP01942981 A EP 01942981A EP 1309728 A2 EP1309728 A2 EP 1309728A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- highly parallel
- polymorphisms
- probes
- parallel characterization
- allele
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 80
- 102000054765 polymorphisms of proteins Human genes 0.000 title claims abstract description 48
- 238000004458 analytical method Methods 0.000 title claims abstract description 29
- 239000000523 sample Substances 0.000 claims abstract description 65
- 108700028369 Alleles Proteins 0.000 claims abstract description 51
- 238000012512 characterization method Methods 0.000 claims abstract description 35
- 238000006243 chemical reaction Methods 0.000 claims abstract description 30
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 16
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 16
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 16
- 238000006911 enzymatic reaction Methods 0.000 claims abstract description 4
- 230000011987 methylation Effects 0.000 claims description 19
- 238000007069 methylation reaction Methods 0.000 claims description 19
- 108091034117 Oligonucleotide Proteins 0.000 claims description 16
- 238000004949 mass spectrometry Methods 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 15
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 11
- 238000003795 desorption Methods 0.000 claims description 10
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 102000004533 Endonucleases Human genes 0.000 claims description 4
- 108010042407 Endonucleases Proteins 0.000 claims description 4
- 238000005804 alkylation reaction Methods 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000005546 dideoxynucleotide Substances 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 229940079826 hydrogen sulfite Drugs 0.000 claims description 3
- 230000000155 isotopic effect Effects 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 238000002966 oligonucleotide array Methods 0.000 claims description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 230000030933 DNA methylation on cytosine Effects 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- CSABAZBYIWDIDE-UHFFFAOYSA-N sulfino hydrogen sulfite Chemical compound OS(=O)OS(O)=O CSABAZBYIWDIDE-UHFFFAOYSA-N 0.000 claims 1
- 230000007067 DNA methylation Effects 0.000 abstract description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000002853 nucleic acid probe Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 44
- 108020004414 DNA Proteins 0.000 description 29
- 238000003556 assay Methods 0.000 description 6
- 238000003205 genotyping method Methods 0.000 description 6
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 6
- 108091092878 Microsatellite Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002974 pharmacogenomic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- BRARRAHGNDUELT-UHFFFAOYSA-N 3-hydroxypicolinic acid Chemical compound OC(=O)C1=NC=CC=C1O BRARRAHGNDUELT-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WRRQHEMZOCFTQP-UHFFFAOYSA-N 2,2,2-trihydroxy-1-phenylethanone Chemical compound OC(O)(O)C(=O)C1=CC=CC=C1 WRRQHEMZOCFTQP-UHFFFAOYSA-N 0.000 description 1
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 1
- JWESTWISAMMBBU-UHFFFAOYSA-N 4-[4-[1-(9h-fluoren-9-ylmethoxycarbonylamino)ethyl]-2-methoxy-5-nitrophenoxy]butanoic acid Chemical compound C1=C(OCCCC(O)=O)C(OC)=CC(C(C)NC(=O)OCC2C3=CC=CC=C3C3=CC=CC=C32)=C1[N+]([O-])=O JWESTWISAMMBBU-UHFFFAOYSA-N 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- VACPHADLPQIWHS-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) butanedioate;ethane-1,2-diol Chemical compound OCCO.O=C1CCC(=O)N1OC(=O)CCC(=O)ON1C(=O)CCC1=O VACPHADLPQIWHS-UHFFFAOYSA-N 0.000 description 1
- OMWQUXGVXQELIX-UHFFFAOYSA-N bitoscanate Chemical compound S=C=NC1=CC=C(N=C=S)C=C1 OMWQUXGVXQELIX-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- SSJMWLROUBFBOB-UHFFFAOYSA-N methyl 2-cyano-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound COC(=O)C(C#N)=CC1=CC=C(O)C=C1 SSJMWLROUBFBOB-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
Definitions
- the present invention describes a high throughput analysis method for the parallel characterization of polymorphisms, in particular SNPs.
- the method for analyzing DNA methylation can be used simultaneously or in a separate experiment.
- the human genome project the first sequencing of the human genome, will be completed in the next few years. This project will make it possible to identify all of the approximately 100,000 genes.
- the sequence information opens up unimagined possibilities for the elucidation of gene functions. This in turn opens up the possibility of doing pharmacogenetics and pharmacogenomics.
- Pharmacogenetics and pharmacogenomics target the use of drugs depending on a genotype. The aim is to increase the effectiveness of medication.
- the necessary intermediate step is to determine the polymorphisms and genotypes associated with a particular response. Therefore, increasingly efficient genotyping methods are required.
- Microsatellites are highly polymorphic, ie they have a large number of alleles. They are characterized in that a repetitive sequence element with a different number of repetitions for different alleles is flanked by conserved sequences. There is an average of one microsatellite marker per million bases. A map of 5,000 positioned microsatellite markers has been published by CEPH (Dil. C., et al. Nature, March 14, 1994). Microsatellites are through ⁇ ⁇ rO (V)
- CD d ⁇ Q rr I- 1 li O 0 N 0 s: 0 ⁇ - O ⁇ J d rt o ⁇ ? Hi 0 li ⁇ HS 0 ⁇ ⁇ 0 3 3 s: co ⁇ -. 0 0 li rt ffi Hl ⁇ o ⁇ - ⁇ - H iQ o-, C ⁇ JN PJ tc 0 ⁇ ⁇ - PJ O PJ: ⁇ • ⁇ d: ⁇ do co ⁇ J
- oligonucleotide covers the sequence from the 5 'side right up to the SNP, so that the SNP joins the 3' end of this oligonucleotide.
- a structurally active endonuclease removes the 5 'overhang from the fully complementary oligonucleotide.
- the trimmed overhang is analyzed using mass spectrometry and used to identify the allele.
- a disadvantage of the method shown is that the products have to be cleaned thoroughly before the mass spectrometric analysis. Magnetic beads that are not easy to use are used for this purification. This is a major disadvantage of many genotyping methods that use mass spectrometry for analysis.
- Another genotyping method is the Taq Man Assay. In this allele-specific enzyme-specific separation of a fluorescence quencher from a fluorescence dye-bearing 0-ligonucleotide is carried out.
- MALDI Matrix-assisted laser desorption / ionization time-of-flight mass spectrometry
- MALDI has revolutionized the analysis of biomolecules (Karas, M. & Hillenkamp, F. Anal. Chem. 60, 2299-2301 (1988)).
- MALDI has been used in various variants for the analysis of DNA. The variants range from primer extension to sequencing (Liu, Y.-H., et al. Rapid Commun. Mass Spectrom. 9, 735-743 (1995); Ch'ang, L.-Y., et al. Rapid Commun Mass Spectrom. 9, 772-774 (1995); Little, DP, et al. J. Mol, Med. 75, 745-750 (1997); Haff, L. & Smirnov, IP Genome Res. 7, 378- 388 (1997), Fei, Z., Ono, T. & Smith, LM
- the object of the present invention is to provide a method for highly parallel genotyping of polymorphisms.
- the problem is solved by a method for the highly parallel characterization of polymorphisms, whereby one carries out the following steps: a) a set of probes, which is provided with at least one detectable marking which is characteristic of the respective probe, is bound to an addressed surface, the binding of the probes generated to the surface being cleavable again photochemically, chemically or enzymatically ; b) a nucleic acid to be investigated is hybridized to these probes; c) the probes are changed in an allele-specific enzymatic reaction; d) a part of the probes is removed which is meaningless for the analysis of the allele-specific reaction; e) the allele-specific products are analyzed on the basis of the detectable markings and the alleles present in the nucleic acid sample queried are determined.
- the address of the surface in step a) is the position (oligonucleotide array), a color, a fluorescent label, an isotopic label, a chemical label or a radioactive label.
- the probes are oligonucleotides, modified oligonucleotides, peptide nucleic acids (PNAs), chimera of these classes of compounds or other substances which interact with DNA in a sequence-specific manner.
- PNAs peptide nucleic acids
- the probes are bound to the surface via reversible binding systems.
- the nucleic acids to be examined in step b) are genomic DNA, nated DNA, cDNA, RNA, PCR products or ligation products.
- the probes are converted into specific products according to step c) depending on the respective sequence of the template hybridized thereon by means of a polymerase and nucleotide building blocks.
- sequencing is carried out by simultaneous use of deoxy and dideoxynucleotide building blocks and not only polymorphisms are detected.
- the probes are converted into specific products in accordance with step c) depending on the particular sequence of the template hybridized thereon by means of a ligase and a phosphorylated oligonucleotide.
- the probes are cut in an all-specific manner as a function of the respective sequence of the template hybridized thereon by means of a helper oligonucleotide and a structurally active endonuclease. It is also preferred that the allele-specific products are analyzed by means of mass spectrometry.
- MALDI matrix-assisted laser desorption / ionization mass spectrometry
- electrospray ionization mass spectrometry is used for the analysis.
- the allele-specific products are present in a manner that is particularly well suited for mass spectrometric analysis. It is further preferred according to the invention that the allele-specific products according to step d) are shortened using an enzymatic or chemical method. It is particularly preferred that the particularly good suitability for mass spectrometric analysis arises from the fact that the allele-specific products have a net simply positive or simply negative charge. It is further preferred that a chemical reaction is used to neutralize charges that would otherwise contribute to a neutral or multiple negative net charge of the product. Thus, it is also preferred that the phosphate groups, thiophosphate groups or dithiophosphate groups of the oligonucleotide backbone are charge neutralized by a selective alkylation reaction. It is also particularly preferred according to the invention that the simple charge is achieved according to the invention by introducing a chemical function which carries the charge.
- the reversible binding chemistry contributes the simple charge to the product by means of an induced break. It is preferred that the induced bond break occurs chemically or photochemically. It is further preferred that the induced bond break occurs during a desorption process of the analysis process.
- a matrix is applied to the surface which supports the desorption in the MALDI process. It is again preferred that the induced bond break is induced by the matrix.
- a multiplicity of are different probes. It is further preferred that allele-specific products of the probes result in an unambiguous mass as a detectable label in the analysis after the allele-specific reaction after step c) after cleavage from the surface. In addition, it is preferred that allele-specific products of the probes result in an unambiguous pattern of fragment masses as a detectable label by the allele-specific reaction after step c) after cleavage from the surface in the analysis. It is particularly preferred here that the masses of all products or product fragments of the allele-specific reactions allow a clear conclusion to be drawn about the alleles present in the nucleic acid queried.
- known polymorphisms are genotyped in the DNA to be examined.
- unknown polymorphisms are identified in the DNA to be examined.
- cytosine methylations are detected and visualized.
- the chemical treatment of the DNA is carried out with a bisulfite solution (disulfite, hydrogen sulfite).
- the amplification is carried out by means of the polymerase reaction (PCR).
- the invention thus describes a method for the highly parallel characterization of polymorphisms.
- a set of probes are bound to an addressed surface.
- the probes used are preferably oligonucleotides, modified oligonucleotides, peptide nucleic acids (PNAs), chimera of these classes of compounds or other substances which interact with DNA in a sequence-specific manner.
- PNAs peptide nucleic acids
- the respective probe is provided with a characteristic, detectable marking.
- This marking is particularly preferably the mass of a fragment of the probe.
- the addressing of the surface is the position (oligonucleotide array), a color, a fluorescent label, an isotopic label, a chemical label or a radioactive label.
- the generated binding of the probes to the surface can be cleaved again photochemically, chemically or enzymatically.
- the probes are bound to the surface via reversible binding systems.
- the nucleic acid to be investigated which is preferably composed of genomic DNA, cloned DNA, pretreated DNA, cDNA, RNA, is hybridized. PCR products or ligation products exist on said probes.
- the DNA is preferably treated beforehand with a bisulfite solution (disulfite, hydrogen sulfite).
- the probes are changed in an allele-specific enzymatic reaction.
- the probes are converted into specific products by means of a polymerase and nucleotide building blocks, depending on the particular sequence of the hybridized template.
- the probes are converted into specific products by means of a ligase and a phosphorylated oligonucleotide, depending on the particular sequence of the hybridized template.
- the probes are then cut allele-specifically, depending on the particular sequence of the template hybridized thereon, with a helper oligonucleotide and a structurally active endonuclease.
- methylation patterns in the pretreated DNA to be analyzed can be examined.
- SNPs are examined in the pretreated DNA to be analyzed.
- a large number of different probes are preferably located on an addressed analysis point on the surface.
- the allele-specific products are preferably shortened using an enzymatic or chemical method.
- the allele-specific products are analyzed on the basis of the detectable markings and the determination of the alleles present in the queried nucleic acid sample is carried out.
- the allele-specific products are analyzed by means of mass spectrometry.
- the allele-specific products are preferably in a type which is particularly suitable for mass spectrometric analysis.
- the particularly good suitability for mass spectrometric analysis preferably arises from the fact that the allele-specific products are net positively or simply negatively charged.
- a chemical reaction is used to neutralize charges, which would otherwise contribute to a neutral or multiple negative net charge of the product.
- phosphate groups, thiophosphate groups or dithi Charge neutralized ophosphate groups of the oligonucleotide backbone by a selective alkylation reaction.
- the simple charge comes about by introducing a chemical function that carries the charge.
- the reversible binding chemistry preferably contributes the simple charge to the product through an induced break.
- the induced bond break occurs chemically or photochemically.
- the induced bond break takes place during the desorption process of the analysis process.
- a matrix is preferably applied to the surface that supports desorption in the MALDI process.
- the induced breaking of the bond is induced by the matrix.
- matrix-assisted laser desorption / ionization mass spectrometry (MALDI) or electron spray ionization mass spectrometry are used for the analysis.
- the extension products of the probes result in an unambiguous mass as detectable marking in the analysis due to the allele-specific reaction after being split off from the surface.
- Known polymorphisms can thus preferably be identified in the DNA to be examined.
- the extension products of the probes result from the allele-specific reaction after cleavage from the surface in the analysis, a clear pattern of fragment masses as a detectable label. Unknown polymorphisms can thus preferably be identified in the DNA to be examined.
- Fig. La and lb an illustration of the process steps using an example
- Fig. 2 shows a possible immobilization of the probes on the 0- surface comprising a photolabile linker.
- FIGS. 1 a and 1 b The following steps are shown in FIGS. 1 a and 1 b:
- the nucleic acid to be investigated is then hybridized to the probe.
- the probes are then extended in an allele-specific reaction. 4.
- the nucleic acid to be examined is removed. 5. Subsequently, a part of the probes is removed which is meaningless for the allele-specific reaction.
- a mass spectrometer is preferably used for the analysis, which identifies the elongated probes on the basis of their masses and which at the same time enables detachment from the surface (eg photolytic reaction in a laser desorption mass spectrometer).
- FIG. 2 shows a possible linkage of the primers to the surface.
- the nucleotide shown is part of the primer, which is not shown for the sake of clarity.
- the genomic DNA sample to be analyzed is first subjected to a bisulfite reaction in which, as is known to the person skilled in the art, non-methylated cytosine residues are converted into uracil residues.
- the fragment of the bisulfited DNA to be analyzed is then amplified by a polymerase chain reaction using specific primers.
- a template-directed extension of the primer TCTATTTACTTCATTCCACTTAAsT * sC is catalyzed by thermosequenase.
- the bisulfite-treated and amplified by means of a PCR reaction serves as a template for the primer extension
- the primer has two phosphothioate bonds which are particularly marked by "s".
- the base of the penultimate monomer here particularly marked by "* ⁇ ", is modified with a substituent bearing a quaternary amino function.
- the primer extension is carried out in the presence a mixture of phosphothioate-modified dideoxynucleotides, the incorporation of which leads to the formation of a third phosphothioate bond at the 3 'end of the primer extended by one nucleotide block.
- a mixture of ⁇ -sddATP and ⁇ -sddGTP is used, so that this corresponds to the methylation status of the template on which the underlying genomic DNA sample is based
- a mixture of the extension products TCTATTTACTTCATTCCACTTAAsT * sCsA and TCTATTTACTT-CATTCCACTTAAsT * sCsG which do not have a 3 'hydroxyl group, is initiated by a three-minute denaturation step at 95 ° C and then analogous to a PCR reaction forty cycles performed.
- the pH is lowered to below 7.0 by adding acetic acid.
- the reaction solution is incubated at 37 ° C for 45 minutes. During this time, the DNA Teplat is completely digested, while the extended primer is only incompletely digested while maintaining the phosphothioate bonds to form the hydrolysis products AsT * sCsA and AsT * sCsG.
- Example ⁇ -cyano-4-hydroxycinnamic acid methyl ester mixed, and applied to a MALDI target.
- the measurement was carried out on a Bruker Reflex II TOF mass spectrometer in positive ion mode.
- FIG. 3 shows spectra which can be assigned to different degrees of methylation of the investigated methylation site in the genomic DNA sample.
- Figures 3-5 show MALDI-TOF spectra obtained after analyzing the methylation status of the first methylation site of exon 14 of the factor VIII gene in accordance with Example 1:
- Fig. 3 The methylation position was completely methylated in the genomic DNA (primer extension by ⁇ -sddGTP)
- Fig. 4 Methylation position was partially methylated in the genomic DNA (primer extension by both ⁇ -sddGTP and ⁇ -sddATP)
- the example describes the execution of the assay set out in the first example in slide format.
- the surface of slides offers the possibility of completely removing excess reagents after each individual step by means of suitable washing processes.
- Untreated slides are washed and chemically treated with an aminosilane.
- one or more spacers such as aminoethoxyethoxyacetic acid (AEEA) can be coupled using suitable chemical methods.
- the terminal amino group is then provided with a photochemically cleavable linker group, preferably 4- [4- (1- (Fmocamino) ethyl) -2-methoxy-5-nitrophenoxy) butyric acid.
- a homobifunctional reagent such as, for example, ethylene glycol bis-succinimidyl succinate (Pierce) in accordance with the manufacturer's instructions.
- Various amino-modified primers such as TCTATTTACTTCATTCCACTTAAsT ⁇ C can now be covalently immobilized on the surface obtained.
- TCTATTTACTTCATTCCACTTAAsT ⁇ C can now be covalently immobilized on the surface obtained.
- the primer is extended on the slide surface in analogy to the 1st example, forming a surface-bound mixture of the extension products TCTATT- TACTTCATTCCACTTAAsT * CsA and TCTATTTACTTCATTCCACT- TAAsT ff CsG.
- the 5 '-phosphorodiesterase digestion and the subsequent methylation of the phophhothioate bonds remaining in the degradation products are also carried out analogously to the first example, with the entire slide or a defined section of its surface being brought into contact with the corresponding reagents. After the methylation has taken place, the slide is washed with a suitable solvent before the photoliker is cleaved by irradiation with UV light of a suitable wavelength.
- the resulting cleavage products contain two positions from the 3 'end which removes a phosphodiester bond which is not methylated under the alkylation conditions and whose negative charge provides highly sensitive detection of the reaction products
- MALDI-TOF enables.
- the MALDI measurement is carried out in negative ion mode directly on the slide surface.
- a matrix solution such as hydroxypicolinic acid or trihydroxyacetophenone
- the measured masses of the fragments resulting from the primer extension products in conjunction with their relative intensity, allow the methylation status of the investigated methylation position in the original DNA to be determined in analogy to the first example.
- This example describes another way to
- the methylation of the phosphothioate bonds in the primer extension products is carried out directly after the extension reaction Digestion is carried out in a position-specific manner by precisely applying a droplet of enzyme solution to a freely selectable position on the slide surface and then incubating at 100 percent atmospheric humidity.
- the nuclease digestion results in the detachment of the alkylated P on the one hand Rimer extension products from the slide surface and on the other hand in the formation of the same products as under Example 1, which can be detected with high sensitivity by MALDI-TOF measurement in positive ion mode.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10021204 | 2000-04-25 | ||
| DE10021204A DE10021204A1 (de) | 2000-04-25 | 2000-04-25 | Verfahren zur hochparallelen Analyse von Polymorphismen |
| PCT/DE2001/001607 WO2001081620A2 (fr) | 2000-04-25 | 2001-04-25 | Procede d'analyse hautement parallele de polymorphismes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1309728A2 true EP1309728A2 (fr) | 2003-05-14 |
Family
ID=7640438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP01942981A Withdrawn EP1309728A2 (fr) | 2000-04-25 | 2001-04-25 | Procede d'analyse hautement parallele de polymorphismes |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1309728A2 (fr) |
| AU (1) | AU2001265759A1 (fr) |
| DE (2) | DE10021204A1 (fr) |
| WO (1) | WO2001081620A2 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11410750B2 (en) | 2018-09-27 | 2022-08-09 | Grail, Llc | Methylation markers and targeted methylation probe panel |
| US12435375B2 (en) | 2018-04-02 | 2025-10-07 | Grail, Inc. | Methylation markers and targeted methylation probe panel |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10029914A1 (de) * | 2000-06-19 | 2002-01-03 | Epigenomics Ag | Verfahren zur hochparallelen Analyse von Polymorphismen |
| DE10142643A1 (de) * | 2001-08-31 | 2003-04-24 | Clondiag Chip Tech Gmbh | Detektion von Wechselwirkungen auf Sonden-Arrays |
| DE10159904A1 (de) * | 2001-12-06 | 2003-07-03 | Adnagen Ag | Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür |
| DE202006020290U1 (de) * | 2006-03-13 | 2008-02-28 | Schubert, Adrian | Vorrichtung zur Erkennung und Identifizierung von Zielstrukturen |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311018D0 (en) * | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US5605798A (en) * | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| GB9315847D0 (en) * | 1993-07-30 | 1993-09-15 | Isis Innovation | Tag reagent and assay method |
| US5830655A (en) * | 1995-05-22 | 1998-11-03 | Sri International | Oligonucleotide sizing using cleavable primers |
| US5869242A (en) * | 1995-09-18 | 1999-02-09 | Myriad Genetics, Inc. | Mass spectrometry to assess DNA sequence polymorphisms |
| US6027890A (en) * | 1996-01-23 | 2000-02-22 | Rapigene, Inc. | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays |
| DK0840804T3 (da) * | 1996-01-23 | 2000-07-17 | Rapigene Inc | Fremgangsmåder og sammensætninger til analyse af nukleinsyremolekyler ved anvendelse af størrelsesseparationsteknikker |
| AU2069597A (en) * | 1996-03-04 | 1997-09-22 | Genetrace Systems, Inc. | Methods of screening nucleic acids using mass spectrometry |
| CN1265156A (zh) * | 1997-07-22 | 2000-08-30 | 拉普吉恩公司 | 核酸阵列上进行的扩增及其它酶反应 |
| DE10015797B4 (de) * | 2000-03-26 | 2006-02-02 | Bruker Daltonik Gmbh | Multiplex-Analyse von DNA-Gemischen mittels photolytisch ablesbarer DNA-Chips |
-
2000
- 2000-04-25 DE DE10021204A patent/DE10021204A1/de not_active Ceased
-
2001
- 2001-04-25 EP EP01942981A patent/EP1309728A2/fr not_active Withdrawn
- 2001-04-25 AU AU2001265759A patent/AU2001265759A1/en not_active Abandoned
- 2001-04-25 WO PCT/DE2001/001607 patent/WO2001081620A2/fr not_active Ceased
- 2001-04-25 DE DE10191554T patent/DE10191554D2/de not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0181620A2 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12435375B2 (en) | 2018-04-02 | 2025-10-07 | Grail, Inc. | Methylation markers and targeted methylation probe panel |
| US11410750B2 (en) | 2018-09-27 | 2022-08-09 | Grail, Llc | Methylation markers and targeted methylation probe panel |
| US11685958B2 (en) | 2018-09-27 | 2023-06-27 | Grail, Llc | Methylation markers and targeted methylation probe panel |
| US11725251B2 (en) | 2018-09-27 | 2023-08-15 | Grail, Llc | Methylation markers and targeted methylation probe panel |
| US11795513B2 (en) | 2018-09-27 | 2023-10-24 | Grail, Llc | Methylation markers and targeted methylation probe panel |
| US12410482B2 (en) | 2018-09-27 | 2025-09-09 | Grail, Inc. | Methylation markers and targeted methylation probe panel |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001081620A3 (fr) | 2003-02-13 |
| DE10191554D2 (de) | 2003-06-12 |
| WO2001081620A2 (fr) | 2001-11-01 |
| DE10021204A1 (de) | 2001-11-08 |
| AU2001265759A1 (en) | 2001-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1232287B1 (fr) | Reseau oligomere comportant des oligomeres de pna et/ou d'adn sur une surface | |
| DE10010280B4 (de) | Verfahren zur Detektion von Cytosin-Methylierung in DNA Proben | |
| DE10015797B4 (de) | Multiplex-Analyse von DNA-Gemischen mittels photolytisch ablesbarer DNA-Chips | |
| DE69626196T2 (de) | Dna-diagnostik mittels massenspektrometrie | |
| EP1261740A1 (fr) | Procede de ligase/polymerase pour detecter la methylation de cytosine dans des echantillons d'adn | |
| EP1204765B1 (fr) | Procede de quantification relative de la methylation des bases du type cytosine dans des echantillons d'adn | |
| EP1294945A2 (fr) | Procede pour la mise en evidence de methylations de la cytosine | |
| WO1998007885A1 (fr) | Procede pour la detection d'acides nucleiques par determination de la masse | |
| EP1147228A2 (fr) | Procede d'identification de modeles de methylation de cytosine dans des echantillons d'adn genomiques | |
| DE10010282B4 (de) | Verfahren zur Detektion von Cytosin-Methylierung in DNA Proben | |
| EP1292711B1 (fr) | Procede pour l'analyse ultraparallele de polymorphismes | |
| EP1135526A2 (fr) | Procede d'identification de modeles de methylation de cytosine dans l'adn genomique | |
| EP1204763B1 (fr) | Procede de caracterisation de fragments d'acide nucleique | |
| EP1309728A2 (fr) | Procede d'analyse hautement parallele de polymorphismes | |
| WO2001027317A2 (fr) | Procede permettant de distinguer les modifications de methylation en position 5 | |
| DE10240746A1 (de) | Verfahren zum Nachweis von Nukleinsäuresequenzen mittels spaltbarer Sondenmoleküle | |
| EP1242628B1 (fr) | Procede d'analyse de sequences d'acide nucleique | |
| DE10044543C2 (de) | Verfahren zur Bestimmung des Methylierungsgrades von bestimmten Cytosinen in genomischer DNA im Sequenzkontext 5'-CpG-3' |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20021009 |
|
| AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| 17Q | First examination report despatched |
Effective date: 20040416 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: EPIGENOMICS AG |
|
| RTI1 | Title (correction) |
Free format text: METHOD FOR THE HIGHLY PARALLEL ANALYSIS OF METHYLATION STATUS |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20071101 |